Unknown PHASE2 INTERVENTIONAL 2-arm NCT02947061

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer: a Phase 2, Prospective,Multicenter, Randomised Study

Sponsor: Chinese Academy of Medical Sciences

Conditions Breast Cancer Recurrent

Interventions Capecitabine plus Docetaxel S1 plus Docetaxel

Updated 8 times since 2017 Last updated: Oct 27, 2016 Started: Apr 30, 2015 Primary completion: Apr 30, 2017 Completion: Apr 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02947061, this PHASE2 trial focuses on Breast Cancer Recurrent and remains ongoing. Sponsored by Chinese Academy of Medical Sciences, it has been updated 8 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE2
Dec 2022 — Oct 2023 [monthly]

Unknown Status PHASE2
Jan 2021 — Dec 2022 [monthly]

Unknown Status PHASE2

▶ Show 3 earlier versions

May 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — May 2019 [monthly]

Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Academy of Medical Sciences

Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China